Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus – Tunisia: Belgium sends emergency aid to Tunisia in the fight against COVID-19 Tunisia is currently facing a serious deterioration of its health situation and a sharp increase in hospitalizations

07/23/2021 | 01:55pm EDT

Belgium has decided to provide emergency assistance to Tunisia, following a request transmitted by this country through the European Mechanism of Civil Protection, in the context of the fight against COVID-19. Tunisia is currently facing a serious deterioration of its health situation and a sharp increase in hospitalizations. The country has informed its European partners of specific needs to help it cope with this situation, including in terms of vaccines. The vaccination rate remains very low in the country and the authorities are trying to accelerate the vaccination campaign.

Belgium's assistance will consist of :

150,000 doses of vaccine (AstraZeneca);
Intensive care drugs (Cisatracurium 10mg - 6980 vials and Midazolam 50mg - 9980 vials) from the stock of the FPS Public Health;
Medical equipment for intensive care and personal protective equipment (including gloves and masks) from the stock of the Defense.

The vaccines come from the stock of the FPS Public Health constituted in the framework of the national vaccination campaign in Belgium. The vaccination campaign is progressing very well in Belgium. This stock of AstraZeneca vaccines was no longer to be used in the framework of the campaign, following a reorientation of the campaign.

This aid will leave this Thursday, July 22 from Belgium.

Belgium wishes to express its solidarity with the Tunisian authorities and population, who are facing a difficult phase of the COVID-19 pandemic. International solidarity in the context of such a pandemic is all the more crucial as none of us is safe until we are all safe. Belgium also sees this contribution as an encouragement to the vaccination based on its own experience and the positive effects of vaccination on the health situation.

Distributed by APO Group on behalf of Kingdom of Belgium - Foreign Affairs, Foreign Trade and Development Cooperation.

© African Press Organization, source Press Releases

All news about ASTRAZENECA PLC
02:21aASTRAZENECA : Merck & Co.'s Prostate Cancer Drug Extends Lives in Late-Stage Study
12:31aAstraZeneca's Prostate-Cancer Propel Phase 3 Trial Met Primary Point
09/23ASTRAZENECA : Australia hits vaccine milestone as Melbourne cases hover near record levels
09/23ASTRAZENECA : Vaccination Against Covid-19 Resumes Sept 24
09/23VC DAILY : Biotechs Seek New Skill Set From -2-
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation w..
09/23WALL STREET STOCK EXCHANGE : As smooth as silk
09/23ASTRAZENECA : A Sense of Comfort, Providing Housing to Patients and their Families During ..
09/23ASTRAZENECA : Science Committee appointment (Form 6-K)
09/23ASTRAZENECA : establishes new Sustainability Committee of the Board (Form 6-K)
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 33,3x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,89x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 118,94 $
Average target price 136,23 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.35%184 418
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291